Herein, Dr. Mumbles outlines the action of 2DG, which inhibits glycolysis, a process by which cancer cells obtain most of their energy due to their massive uptake of glucose. Inhibition of glycolysis starves cancer cells of energy, which ultimately translates into inhibited growth and even turnover of cancer cells. 2DG exhibits cytotoxicity against a wide spectrum of cancers but is non-toxic to normal cells because of its unique characteristics.
Discover how it has been explored in both pre-clinical and clinical trials, and elucidate how it is making its way towards the clinic. The video gives a key glimpse into the molecular mechanism behind this molecule as well as describing the biological activity of 2DG. It also highlights how 2DG is a direct target for potential anti-cancer therapy that may unravel the need for further treatments and concepts.
